Big pharma has been looked at as evil because they are profiting off of the sick people rather than finding cures. Eliminating the symptoms and slow the negative affects, this allows the companies to continue to sell. Pfizer makes a variety of drugs and it is important to know where they sell them and who their competition is.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Potential Pfizer investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Pfizer
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Pfizer performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Pfizer shares is the value that is considered the true value of the share. If
the intrinsic value of Pfizer is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Pfizer. Please read more on our
fundamental analysis page.
How effective is Pfizer in utilizing its assets?
Pfizer Inc reports assets on its Balance Sheet. It represents the amount of Pfizer resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Pfizer aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Pharmaceuticals space. To get a better handle on how balance sheet or income statements item affect Pfizer volatility, please check the breakdown of all its
fundamentals.
Are Pfizer Earnings Expected to grow?
The
future earnings power of Pfizer involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Pfizer factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Pfizer
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Pfizer
expected earnings.
And What about dividends?
A dividend is the distribution of a portion of Pfizer earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Pfizer dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Pfizer one year expected dividend income is about USD1.23 per share.
At present, Pfizer's
Dividend Payout Ratio is projected to increase slightly based on the last few years of reporting.
Investing in dividend-paying stocks, such as Pfizer Inc is one of the few strategies that are good for long-term investment. Ex-dividend dates are significant because investors in Pfizer must own a stock before its ex-dividend date to receive its next dividend.
This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Pfizer. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.
Pfizer Gross Profit
Pfizer Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Pfizer previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Pfizer Gross Profit growth over the last 10 years. Please check Pfizer's
gross profit and other
fundamental indicators for more details.
What is driving Pfizer Investor Appetite?
Taking a quick look at the chart using the monthly time frame, we can see that the stock price has slowly increased recently, but may be due for a pull back as the growth is slowing. Still making higher highs and lower lows, the technical indicate is still has room to grow, but the fundamentals may be saying something different.
When looking to invest in the pharmaceutical industry and especially with a company such as Pfizer, they are highly regulated by the government and can spend endless dollars only to have their drugs turned down by the FDA. You want to complete the right amount of research to understand what drugs are being produced and what they are helping, because it could be the first of that kind of drug. However, if a drug fails to get approval by the FDA, it could be devastating because all of that hard work was for not. Certainly they research they can use later, but it means they have to go back and either create a whole new drug or scrap the plans all together.
Also, keep an eye on government regulations because it could affect how the company does business going forward. In such a cash hungry, highly sensitive industry, you really have to know what is going on to help limit your company specific risk whenever possible. The alternative would be to find an ETF that covers this industry and allows you to gain exposure without have high company specific risk.
Before investing, I highly recommend completing very thorough research and finding out everything you can about this company. If you are stuck, certainly reach out to an investing professional as they can help to point you in the right direction. When in doubt, don’t invest and look for another opportunity. There is no reason to risk your hard earned money on an investment you do not fully understand. Pfizer should be around for years to come, but that is never guaranteed. People will always needs their medicine, but it could begin to come from others if Pfizer loses their hold on the market.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Nathan Young is a Senior Member of Macroaxis Editorial Board - US Equity Analysis. With years of experience in the financial sector, Nathan brings a diverse base of knowledge. Specifically, he has in-depth understanding of application of technical and fundamental analysis across different equity instruments. Utilizing SEC filings and technical indicators, Nathan provides a reputable analysis of companies trading in the United States.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nathan Young do not own shares of Pfizer Inc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com